Product Name :
Linifanib
Sequence:
Purity:
≥98% (HPLC)
Molecular Weight:
375.4
Solubility :
Soluble in DMSO (75mg/ml) or ethanol (5mg/ml).
Appearance:
Brown powder.
Use/Stability :
As indicated on product label or CoA when stored as recommended.
Description:
Inhibitor effective against all VEGF and PDGF receptors Linifanib is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers.{{1797406-69-9} medchemexpress|{1797406-69-9} Technical Information|{1797406-69-9} In stock|{1797406-69-9} supplier} The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling.{{1034616-18-6} MedChemExpress|{1034616-18-6} Purity & Documentation|{1034616-18-6} Description|{1034616-18-6} manufacturer} It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world.PMID:28613794 Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in Aml) patient cells via reduction of AKT and GSK3β phosphorylation and maybe influential in Aml therapy.
CAS :
796967-16-3
Solubility:
Soluble in DMSO (75mg/ml) or ethanol (5mg/ml).
Formula:
C21H18FN5O
Additional Information :
| Alternative Name A-741439, ABT-869, RG3635, N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N’-(2-fluoro-5-methylphenyl)-urea | Appearance Brown powder. | CAS 796967-16-3 | Couple Target PDGF receptor, VEGFR | Couple Type Inhibitor | Formula C21H18FN5O | Identity Determined by EM-MS, NMR | MW 375.4 | Purity ≥98% (HPLC) | Solubility Soluble in DMSO (75mg/ml) or ethanol (5mg/ml). | Unit of Measure (UM) mg
